© 2018 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
“We’re a group of young DC kids trying to do something good for the city.”
As a person living with HIV, I speak out for prevention—sometimes on the evening news!
A researcher responds to expanded approval of Truvada as pre-exposure prophylaxis by the Food and Drug Administration.
“Love & Solidarity: Together PrEP, Testing and Treatment Can End HIV”
The approval is based on a small study of 15- to 17-year-olds.
Merck’s investigational antiretroviral could one day be dosed only weekly among HIV-negative humans.
During AIDSWatch 2018, HIV advocates visit Capitol Hill to lobby for the needs of people living with and at risk for HIV. [VIDEO]
The CDC reports that PrEP use is low among Blacks and Latinos.
A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
This sets the stage for an early human trial of such antibody injections for use as pre-exposure prophylaxis (PrEP) against HIV.
The third annual Biomedical HIV Prevention Summit will be held December 3-4, 2018 in LA, California.
Supporting youth leaders to address HIV among Latinos
Pre-exposure prophylaxis has an uncertain future among youth under 25.
Our April/May cover story focuses on Latino youth.
The North Carolina AIDS Action Network fights stigma through education, advocacy and community building.
Phill Wilson is retiring from his post as president and CEO.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
